OxyFile #407

Dr. Mel Krajden Appointed to LifeTECH's Scientific Advisory Board

TORONTO, Oct. 17 1996 /CNW/ - LifeTECH (CDN-LFTK), a biotechnology 
company with proprietary sterilization technology for blood and 
blood products, announced today that Dr. Mel Krajden has been 
appointed to the Corporation's Scientific Advisory Board. The 
Scientific Advisory Board is a group of eminent scientists who 
advise LifeTECH on scientific strategy, review the Corporation's 
research programs and assist in product development.

Mr. Walter J. Dermott, President and Chief Executive Officer, made 
the announcement, saying: "Our Scientific Advisory Board is 
greatly strengthened by the addition of Dr. Krajden, who is one of 
the leading Canadian experts in virology and serology. His 
experience and knowledge will be a real benefit to our Research 
and Development into the inactivation of viruses in blood and 
blood products. Dr. Krajden will be a key part of our efforts to 
make the global blood supply safe."

Dr. Krajden, M.D., FRCP(C), earned his M.D. and received his 
Internal Medicine training at McGill University, then completed 
post doctoral fellowships in Infectious Diseases at Stanford 
University and in Medical Microbiology at the University of 
Toronto. He is currently Section Head, Virology and Serology, at 
the Toronto Hospital, and has served as a Staff Microbiologist and 
Infectious Diseases Consultant at Toronto Western Hospital. Dr. 
Krajden is also an Assistant Professor in the Department of 
Clinical Biochemistry at the University of Toronto. He acts as a 
reviewer for the Journal of Clinical Microbiology and Clinical and 
Diagnostic Virology, and is Associate Editor of the Canadian 
Journal of Infectious Diseases. Dr. Krajden's professional 
publications reflect his significant research into blood borne 
viruses such as Hepatitis C and Cytomegalovirus using nucleic acid 
amplification assays.

LifeTECH Corporation is a Canadian biotechnology company dedicated 
to developing and commercializing innovative technologies to 
sterilize blood and other biological fluids. LifeTECH's 
Sterizone(TM) System is designed to inactivate viruses and 
bacteria in the global blood supply, including the HIV and 
Hepatitis viruses. LifeTECH common shares (LFTK) and warrants 
(LFTK.WT) trade on the Canadian Dealing Network.

From Canada Newswire